Precision medicine in Ewing sarcoma: a translational point of view.
Pablo GargalloA JuanY YáñezS DolzV SeguraV CastelA CañetePublished in: Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico (2020)
Ewing sarcoma is a rare tumor that arises in bones of children and teenagers but, in 15% of the patients it is presented as a primary soft tissue tumor. Balanced reciprocal chimeric translocation t(11;22)(q24;q12), which encodes an oncogenic protein fusion (EWSR1/FLI1), is the most generalized and characteristic molecular event. Using conventional treatments, (chemotherapy, surgery and radiotherapy) long-term overall survival rate is 30% for patients with disseminated disease and 65-75% for patients with localized tumors. Urgent new effective drug development is a challenge. This review summarizes the preclinical and clinical investigational knowledge about prognostic and targetable biomarkers in Ewing sarcoma, finally suggesting a workflow for precision medicine committees.
Keyphrases
- end stage renal disease
- soft tissue
- ejection fraction
- cell therapy
- early stage
- minimally invasive
- locally advanced
- healthcare
- newly diagnosed
- young adults
- radiation therapy
- peritoneal dialysis
- randomized controlled trial
- clinical trial
- squamous cell carcinoma
- coronary artery bypass
- patient reported outcomes
- stem cells
- small molecule
- rectal cancer
- phase ii
- patient reported
- single molecule
- transcription factor
- open label
- radiation induced
- study protocol
- acute coronary syndrome